CD8A and melanoma: Subsequently, they demonstrated that EZH2 inhibitor alone enhanced the cytotoxic activity of human CD8+ effector T cells, altered the phenotype and function of human Treg cells, and had an immunotherapy-sensitizing effect against CTLA-4 in mouse bladder cancer and melanoma models (121, 134).